CAPTRUST Financial Advisors
BTAI icon

CAPTRUST Financial Advisors’s BioXcel Therapeutics BTAI Stock Holding History

CAPTRUST Financial Advisors’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3
Closed -$1K – 4941
2022
Q1 		$1K Buy
3
+2
+200% +$580 ﹤0.01% 4660
2021
Q4 		$0 Sell
1
-16
-94% -$6.87K ﹤0.01% 4769
2021
Q3 		$8K Hold
17
– – ﹤0.01% 3721
2021
Q2 		$8K Sell
17
-1
-6% -$545 ﹤0.01% 3650
2021
Q1 		$12K Sell
18
-176
-91% -$142K ﹤0.01% 3327
2020
Q4 		$143K Hold
194
– – ﹤0.01% 1341
2020
Q3 		$139K Buy
194
+178
+1,113% +$134K ﹤0.01% 1197
2020
Q2 		$13K Buy
+16
New +$10.4K ﹤0.01% 2090

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

CAPTRUST Financial Advisors's BTAI Position: Q2 2022 in Review

CAPTRUST Financial Advisors sold out of BioXcel Therapeutics (BTAI) in Q2 2022, closing a stake of 3 shares — an estimated $1K sold.

CAPTRUST Financial Advisors first reported a position in BTAI in Q2 2020 and held it in 8 quarters. The position peaked at $143K in Q4 2020. 94 funds tracked by Wall St. Rank hold BTAI as of Q2 2022.

  • CAPTRUST Financial Advisors reported no remaining BioXcel Therapeutics position as of Q2 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 3 BioXcel Therapeutics shares in Q2 2022, an estimated $1K.
  • CAPTRUST Financial Advisors first reported a position in BioXcel Therapeutics in Q2 2020 and held it in 8 quarters.
  • CAPTRUST Financial Advisors's BioXcel Therapeutics position peaked at $143K in Q4 2020.
  • 94 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2022, filed 16 Aug 2022.